A First-in-human (FIH) Combination Treatment Study With a Single Dose Level of BMC128

A live bio-therapeutic product composed of 4 commensal bacterial strains, natural inhabitants of the human intestinal tract.

A human monoclonal antibody that blocks programmed-death-1 (PD-1). It is a type of immunotherapy and works as a checkpoint inhibitor, blocking a signal that prevents activation of T cells from attacking the cancer.